Testing combination drugs for advanced blood cancer that didn't respond to prior treatment

Plain-English translation of NCT04560322 on ClinicalTrials.gov ↗ · Source last updated April 2026 · Translation generated August 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing a combination treatment using -, with the possible addition of , for people whose blood cancer has not responded to or has come back after previous treatment. The study uses special blood tests to check how well the treatment is working, and may add a third medication if needed. The goal is to find the best way to eliminate the cancer cells.

While each of these medications has been approved by the FDA individually for treating blood cancer, doctors want to know if using them together—and adjusting the treatment based on how well it's working—can help patients whose cancer is difficult to treat.

Do you qualify?

You likely qualify if…

you have been diagnosed with chronic lymphocytic leukemia or small lymphocytic lymphoma
your cancer has come back or did not respond to at least one previous treatment
your disease is considered high or intermediate risk based on specific blood and protein markers
you are at least 18 years old and able to handle treatment (your doctor will assess this)
you have adequate liver, kidney, and bone marrow function based on blood tests

You likely don't qualify if…

you have previously been treated with a BTK inhibitor or BCL2 inhibitor (with rare exceptions for patients who had very good responses)
you are pregnant or breastfeeding, or unable to use reliable contraception during and after treatment
you have severely low blood cell counts or organ damage that would make treatment unsafe

What participation looks like

You would receive as infusions on specific days during the first cycle, then monthly, and take as a daily oral pill. Your blood will be tested regularly using a special test called ClonoSEQ to see how well the treatment is working. Depending on those results, you may continue on the current medications, or may be added as a third daily pill. Treatment typically lasts 1–2 years, with visits to the clinic for infusions, blood draws, and check-ins with your doctor.

AI-generated summary from trial data · Aug 2, 2026 · Not medical advice

Trial locations(3 sites)

United States

Massachusetts General Hospital Cancer Center, Boston, Massachusetts

Beth Israel Deaconess Medical Center, Boston, Massachusetts

Dana-Farber Cancer Institute, Boston, Massachusetts